These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7829609)

  • 1. Adrenocorticotropin hyperresponse to the corticotropin-releasing hormone-mediated stimulus of naloxone in patients with myotonic dystrophy.
    Grice JE; Jackson RV; Hockings GI; Torpy DJ; Walters MM; Crosbie GV
    J Clin Endocrinol Metab; 1995 Jan; 80(1):179-84. PubMed ID: 7829609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen response to hypothalamic-pituitary-adrenal stimulation with naloxone in women with myotonic muscular dystrophy.
    Buyalos RP; Jackson RV; Grice GI; Hockings GI; Torpy DJ; Fox LM; Boots LR; Azziz R
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3219-24. PubMed ID: 9745431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradoxical inhibition by aspirin of naloxone-induced adrenocorticotropin secretion in myotonic dystrophy.
    Hockings GI; Jackson RV; Grice JE; Crosbie GV; Walters MM; Torpy DJ; Jackson AJ
    J Clin Endocrinol Metab; 1994 Jun; 78(6):1424-7. PubMed ID: 8200945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered hypothalamic-pituitary-adrenal axis responsiveness in myotonic dystrophy: in vivo evidence for abnormal dihydropyridine-insensitive calcium transport.
    Hockings GI; Grice JE; Crosbie GV; Walters MM; Jackson RV
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1433-8. PubMed ID: 8388880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of naloxone-stimulated adrenocorticotropin release by alprazolam in myotonic dystrophy patients.
    Joyner JM; Grice JE; Hockings GI; Torpy DJ; Crosbie GV; Walters MM; Jackson RV
    J Neuroendocrinol; 1998 May; 10(5):391-5. PubMed ID: 9663654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of stimulated and spontaneous adrenocorticotropin secretory dynamics identifies distinct components of cortisol feedback inhibition in healthy humans.
    Dorin RI; Ferries LM; Roberts B; Qualls CR; Veldhuis JD; Lisansky EJ
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3883-91. PubMed ID: 8923833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated basal adrenocorticotropin and evidence for increased central opioid tone in highly trained male athletes.
    Inder WJ; Hellemans J; Ellis MJ; Evans MJ; Livesey JH; Donald RA
    J Clin Endocrinol Metab; 1995 Jan; 80(1):244-8. PubMed ID: 7829620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of naloxone administration on the secretion of corticotropin-releasing hormone, arginine vasopressin, and adrenocorticotropin in unperturbed horses.
    Alexander SL; Irvine CH
    Endocrinology; 1995 Nov; 136(11):5139-47. PubMed ID: 7588252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin increases the human hypothalamic-pituitary-adrenal axis response to naloxone stimulation.
    Hockings GI; Grice JE; Crosbie GV; Walters MM; Jackson AJ; Jackson RV
    J Clin Endocrinol Metab; 1993 Aug; 77(2):404-8. PubMed ID: 8393884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of repetitive administration of corticotropin-releasing hormone combined with lysine vasopressin on plasma adrenocorticotropin and cortisol levels in secondary adrenocortical insufficiency.
    Fukata J; Usui T; Tsukada T; Nakai Y; Koh T; Ishihara T; Tanaka I; Uchida K; Yoshimasa T; Nakano R
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1624-31. PubMed ID: 2172283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of desipramine on basal and naloxone-stimulated cortisol secretion in humans: interaction of two drugs acting on noradrenergic control of adrenocorticotropin secretion.
    Torpy DJ; Grice JE; Hockings GI; Crosbie GV; Walters MM; Jackson RV
    J Clin Endocrinol Metab; 1995 Mar; 80(3):802-6. PubMed ID: 7883833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alprazolam attenuates vasopressin-stimulated adrenocorticotropin and cortisol release: evidence for synergy between vasopressin and corticotropin-releasing hormone in humans.
    Torpy DJ; Grice JE; Hockings GI; Walters MM; Crosbie GV; Jackson RV
    J Clin Endocrinol Metab; 1994 Jul; 79(1):140-4. PubMed ID: 8027217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responsivity of adrenocorticotropin to corticotropin-releasing hormone and lack of suppressibility by dexamethasone are related phenomena in Cushing's disease.
    Hermus AR; Pieters GF; Pesman GJ; Smals AG; Benraad TJ; Kloppenborg PW
    J Clin Endocrinol Metab; 1986 Apr; 62(4):634-9. PubMed ID: 3005353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the effects of human and ovine corticotropin-releasing hormone on the pituitary-adrenal axis.
    Trainer PJ; Faria M; Newell-Price J; Browne P; Kopelman P; Coy DH; Besser GM; Grossman AB
    J Clin Endocrinol Metab; 1995 Feb; 80(2):412-7. PubMed ID: 7852498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A synergistic adrenocorticotropin response to naloxone and vasopressin in normal humans: evidence that naloxone stimulates endogenous corticotropin-releasing hormone.
    Hockings GI; Grice JE; Walters MM; Crosbie GV; Torpy DJ; Jackson RV
    Neuroendocrinology; 1995 Feb; 61(2):198-206. PubMed ID: 7753339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of exogenous atrial natriuretic peptide on the pituitary-adrenal response to corticotropin-releasing hormone and vasopressin in healthy men.
    Bierwolf C; Burgemeister A; Lüthke K; Born J; Fehm HL
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1151-7. PubMed ID: 9543132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of metyrapone pretreatment on adrenocorticotropin secretion induced by corticotropin-releasing hormone in normal subjects and patients with Cushing's disease.
    Totani Y; Niinomi M; Takatsuki K; Oiso Y; Tomita A
    J Clin Endocrinol Metab; 1990 Mar; 70(3):798-803. PubMed ID: 2155255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sodium valproate on naloxone-stimulated ACTH and cortisol release in humans.
    Torpy DJ; Grice JE; Hockings GI; Crosbie GV; Walters MM; Jackson RV
    Clin Exp Pharmacol Physiol; 1995; 22(6-7):441-3. PubMed ID: 8582096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased pro-opiomelanocortin-derived peptide release in myotonic dystrophy.
    Jackson RV; Fleming GA; Sussman CR; Atkinson AB; Decherney GS; Debold CR; Davis DR; Nicholson WE; Island DP; Rabin D
    Aust Paediatr J; 1988; 24 Suppl 1():70-3. PubMed ID: 2849397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.
    Ghigo E; Arvat E; Ramunni J; Colao A; Gianotti L; Deghenghi R; Lombardi G; Camanni F
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2439-44. PubMed ID: 9253314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.